Sylwia Wosko
Overview
Explore the profile of Sylwia Wosko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serefko A, Lachowicz-Radulska J, Szopa A, Herbet M, Czylkowska A, Ignatiuk K, et al.
Molecules
. 2025 Feb;
30(3).
PMID: 39942624
The objective of this study was to assess the antidepressant efficacy of a novel imipramine-magnesium (IMI-Mg) complex in comparison to the administration of imipramine and magnesium individually. The study utilized...
2.
Stepnicki P, Wosko S, Bartyzel A, Zieba A, Bartuzi D, Szalaj K, et al.
Molecules
. 2023 May;
28(10).
PMID: 37241951
The dopamine D receptor, which belongs to the family of G protein-coupled receptors (GPCR), is an important and well-validated drug target in the field of medicinal chemistry due to its...
3.
Wosko S, Serefko A, Szopa A, Kardas S, Widelski J, Mroczek T, et al.
Life (Basel)
. 2021 Nov;
11(11).
PMID: 34832993
Depression is one of the most common mental disorders in the world that negatively affects the daily functioning of patients. Numerous studies are currently being conducted to examine the antidepressant...
4.
Szopa A, Bogatko K, Herbet M, Serefko A, Ostrowska M, Wosko S, et al.
Int J Mol Sci
. 2021 Mar;
22(4).
PMID: 33673282
The purpose of the study was to investigate whether the co-administration of Mg and Zn with selective A1 and A2A receptor antagonists might be an interesting antidepressant strategy. Forced swim,...
5.
Poleszak E, Wosko S, Slawinska K, Wyska E, Szopa A, Swiader K, et al.
Pharmacol Rep
. 2020 Mar;
72(6):1562-1572.
PMID: 32221841
Background: Though there are several classes of antidepressant drugs available on the pharmaceutical market, depression that affects globally over 320 million people is still undertreated. Scientists have made attempts to...
6.
Poleszak E, Wosko S, Slawinska K, Wyska E, Szopa A, Swiader K, et al.
Pharmacol Biochem Behav
. 2019 Dec;
188:172833.
PMID: 31785246
Available data support the notion that cannabinoids, whose therapeutic value is limited due to severe adverse reactions, could be beneficial as adjunctive agents in the management of mood disorders. Polytherapy,...
7.
Poleszak E, Wosko S, Slawinska K, Wyska E, Szopa A, Sobczynski J, et al.
Behav Brain Res
. 2019 Oct;
378:112297.
PMID: 31626848
Although a lot of information can be found on the specific dual role of the endocannabinoid system in the emotional-related responses, little is known whether stimulation or inhibition of the...
8.
Szopa A, Bogatko K, Serefko A, Wyska E, Wosko S, Swiader K, et al.
Pharmacol Rep
. 2019 Jun;
71(4):676-681.
PMID: 31200233
Background: Adenosine, an endogenous nucleoside, modulates the release of monoamines, e.g., noradrenaline, serotonin, and dopamine in the brain. Both nonselective and selective stimulation of adenosine receptors produce symptoms of depression...
9.
Poleszak E, Wosko S, Slawinska K, Wyska E, Szopa A, Doboszewska U, et al.
Brain Res Bull
. 2019 Jun;
150:179-185.
PMID: 31158462
Antidepressants that target the monoaminergic system are prescribed most frequently in the psychiatric practice. However, not all patients benefit from their use. It is generally known that co-administration of agents...
10.
Poleszak E, Wosko S, Slawinska K, Szopa A, Wrobel A, Serefko A
Life Sci
. 2018 Oct;
213:18-24.
PMID: 30290188
Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others have been...